What is the lifelong maintenance dose of Eliquis (apixaban)?

Maintenance Dose of Eliquis (Apixaban) for Lifelong Anticoagulation

For most patients requiring lifelong anticoagulation with Eliquis, the standard maintenance dose is 5 mg orally twice daily. 1

Standard Dosing for Atrial Fibrillation

• The FDA-approved and guideline-recommended maintenance dose for stroke prevention in nonvalvular atrial fibrillation is 5 mg twice daily for the majority of patients. 1, 2
• This standard dose applies across a broad spectrum of renal function, from normal kidney function down to severe impairment (CrCl 15-50 mL/min), and even in patients on dialysis. 3

Dose Reduction Criteria: The "Two-of-Three" Rule

Dose reduction to 2.5 mg twice daily is indicated ONLY when a patient meets at least TWO of the following three criteria: 1, 3

• Age ≥ 80 years
• Body weight ≤ 60 kg
• Serum creatinine ≥ 1.5 mg/dL (≥ 133 µmol/L)

Critical Point: Meeting Only ONE Criterion Does NOT Warrant Dose Reduction

• Patients with only one dose-reduction characteristic should receive the standard 5 mg twice daily dose. 3, 4
• The 2024 ACC/AHA/ACCP/HRS guidelines explicitly confirm that dose reduction requires at least two criteria to be present simultaneously. 2, 3
• A 2016 JAMA Cardiology analysis of the ARISTOTLE trial demonstrated that patients with one dose-reduction criterion receiving 5 mg twice daily had consistent efficacy and safety compared to those with no criteria, with similar hazard ratios for stroke prevention (HR 0.94 vs 0.77) and major bleeding (HR 0.68 vs 0.72). 4

Common Prescribing Error: Inappropriate Underdosing

• Underdosing is the most frequent prescribing error with apixaban, occurring in 9.4-40.4% of prescriptions. 3
• The primary driver is incorrectly reducing the dose to 2.5 mg twice daily when only one criterion is met instead of the required two. 3
• Inappropriate underdosing increases the risk of thromboembolic events without providing additional bleeding protection. 3

Renal Function Considerations

• Creatinine clearance alone does not determine apixaban dosing. 3
• Patients with CrCl 30-50 mL/min who do not meet two dose-reduction criteria should receive 5 mg twice daily. 2, 3
• Even in severe renal impairment (CrCl 15-29 mL/min) or end-stage renal disease requiring dialysis, the two-of-three criteria—not renal function alone—determine whether 5 mg or 2.5 mg twice daily is appropriate. 3, 1
• The 2019 AHA/ACC/HRS guidelines endorse applying the two-of-three criteria in dialysis patients rather than automatically reducing the dose. 3

Special Indications with Different Dosing

Venous Thromboembolism (VTE) Treatment

• Initial treatment (first 7 days): 10 mg twice daily 1
• Maintenance after 7 days: 5 mg twice daily 1

VTE Recurrence Prevention (Extended Therapy)

• After completing at least 6 months of standard anticoagulation for VTE, the dose for long-term recurrence prevention is 2.5 mg twice daily. 1
• Recent 2026 meta-analysis data support reduced-dose DOACs (apixaban 2.5 mg twice daily) for extended cancer-associated VTE treatment, showing lower bleeding risk without increased thrombosis. 5

Post-Surgical Thromboprophylaxis

• Following hip or knee replacement surgery: 2.5 mg twice daily for 12-35 days (not lifelong). 1

Practical Algorithm for Lifelong Maintenance Dosing

Step 1: Identify the indication

• Atrial fibrillation → proceed to Step 2
• VTE treatment (first 6 months) → 5 mg twice daily after initial 7-day loading
• VTE extended prevention (beyond 6 months) → 2.5 mg twice daily

Step 2: For atrial fibrillation, count dose-reduction criteria present:

• Age ≥ 80 years? (Yes/No)
• Weight ≤ 60 kg? (Yes/No)
• Serum creatinine ≥ 1.5 mg/dL? (Yes/No)

Step 3: Apply dosing based on count:

• 0 or 1 criterion present → 5 mg twice daily 3, 1
• 2 or 3 criteria present → 2.5 mg twice daily 3, 1

Key Caveats

• Do not use creatinine clearance calculations alone to determine apixaban dosing in atrial fibrillation; the two-of-three clinical criteria take precedence. 3
• Apixaban has a 12-hour half-life, requiring twice-daily dosing for consistent anticoagulation. 6
• The pharmacodynamic effect persists for at least 24 hours after the last dose (approximately two half-lives). 1
• Avoid apixaban in patients with prosthetic heart valves, as safety and efficacy have not been established in this population. 1
• Recent 2026 data from the COBRRA trial showed apixaban had significantly lower bleeding risk than rivaroxaban for acute VTE treatment (3.3% vs 7.1%, P<0.001), supporting its use when bleeding risk is a concern. 7